Physician profile
Taniya Badwal
NPI 1720863319
$2,623.22
in general payments reported to CMS, 2019-2025
25 companies · $2,558 in 2025
The $2,558 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $64.83 · 2025: $2,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $486.93 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $338.93 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $286.02 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $220.79 | 2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $172.05 | 2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $164.15 | 2025 | Spravato, Invega Sustenna, Invega Trinza |
| Regeneron Healthcare Solutions, INC. | $120.25 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $100.69 | 2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $98.35 | 2025 | |
| Phathom Pharmaceuticals, INC. | $90.63 | 2025 | Voquezna |
| Janssen Biotech, INC. | $72.73 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $61.52 | 2025 | Cobenfy |
| Biogen, INC. | $50.63 | 2025 | Zurzuvae |
| Lilly USA, LLC | $46.21 | 2024-2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $45.26 | 2025 | Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $41.78 | 2025 | Rexulti |
| Incyte Corporation | $40.86 | 2024-2025 | Opzelura |
| Smith+Nephew, INC. | $38.50 | 2024-2025 | Tula |
| Glaxosmithkline, LLC. | $31.99 | 2025 | Nucala |
| Tris Pharma INC | $28.55 | 2025 | Dyanavel Xr |
| Optinose US, INC. | $24.65 | 2025 | |
| Almirall LLC | $20.06 | 2025 | Klisyri |
| Collegium Pharmaceutical, INC. | $17.13 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $15.09 | 2025 | Exxua |
| Corium, LLC | $9.47 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taniya Badwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.